Russell Investments Group
ELVN icon

Russell Investments Group’s Enliven Therapeutics ELVN Stock Holding History

Russell Investments Group’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.67M Buy
91,938
+88,937
+2,964% +$3.78M ﹤0.01% 1545
2026
Q1 		$118K Sell
3,001
-120
-4% -$3.33K ﹤0.01% 3039
2025
Q4 		$48.1K Sell
3,121
-521
-14% -$10.4K ﹤0.01% 3311
2025
Q3 		$74.6K Sell
3,642
-25,905
-88% -$522K ﹤0.01% 3131
2025
Q2 		$593K Sell
29,547
-75,995
-72% -$1.44M ﹤0.01% 2275
2025
Q1 		$2.08M Buy
105,542
+105,471
+148,551% +$2.27M ﹤0.01% 1674
2024
Q4 		$1.6K Buy
71
+59
+492% +$1.53K ﹤0.01% 3479
2024
Q3 		$306 Sell
12
-1,426
-99% -$33K ﹤0.01% 3611
2024
Q2 		$33.6K Buy
1,438
+1,426
+11,883% +$30K ﹤0.01% 2848
2024
Q1 		$211 Hold
12
– – ﹤0.01% 3275
2023
Q4 		$166 Buy
+12
New +$147 ﹤0.01% 3185
2021
Q3 		– Sell
-48,476
Closed -$1.53M – 3083
2021
Q2 		$1.53M Buy
+48,476
New +$1.5M ﹤0.01% 2079

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Russell Investments Group's ELVN Position: Q2 2026 in Review

Russell Investments Group increased its Enliven Therapeutics (ELVN) stake by 2,964% in Q2 2026, buying an estimated $3.78M and bringing the position to 91,938 shares worth $4.67M. The position accounts for ﹤0.01% of the portfolio, ranked #1545.

Russell Investments Group first reported a position in ELVN in Q2 2021 and has held it in 12 quarters since. 213 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Russell Investments Group held 91,938 shares of Enliven Therapeutics worth $4.67M as of Q2 2026.
  • Russell Investments Group bought 88,937 Enliven Therapeutics shares in Q2 2026, an estimated $3.78M.
  • Enliven Therapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #1545 holding.
  • Russell Investments Group first reported a position in Enliven Therapeutics in Q2 2021 and has held it in 12 quarters since.
  • 213 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.